Cardiovascular Disease

Increased CVD Risk for Cancer Survivors

While breakthrough cancer treatments are helping cancer survivors live longer, researchers are learning that survivors face an increased risk of developing cardiovascular disease later in life. 

Johns Hopkins researchers tracked 12,414 study participants’ cardiovascular disease outcomes over a median of 13.6 years (3,250 with a history of cancer). When researchers adjusted for age, sex, race, and education level, they found that cancer survivors had: 

  • 42% higher risk of cardiovascular disease.
  • 59% higher risk of heart failure.

Traditional risk factors, like BMI, cholesterol levels, and drinking and smoking status, could not fully explain the excess risk. Even when adjusting for these variables, researchers found that cancer survivors demonstrated:

  • 37% higher risk of cardiovascular disease.
  • 52% higher risk of heart failure. 

Increased risk levels varied by cancer type. Breast, lung, colorectal, and hematologic/lymphatic cancers were significantly associated with CVD risk, while prostate cancer was not. 

The authors suspect a combination of cancer and noncancer factors is driving survivors’ elevated CVD risks. Possible culprits include genetic predisposition, exposure to toxicities during cancer therapy, and inflammation and oxidative stress associated with cancer.

The Takeaway

It appears that cancer survivors face a higher risk of developing CVD, suggesting that as cancer treatments continue to improve, cardiologists will see even more survivors in their exam rooms. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!